



American
Urological
Association

2024 Annual Meeting Forum Disclosures

Contents	Page
Urologic Care for the Advanced Practice Provider	2
Basic Science Symposium	3
Bladder Cancer Forum	4
Challenges for Urologic Research	11
Diversity, Equity and Inclusion Forum	12
The Evolving Landscape of Prostate Cancer Treatment	13
History of Urology Forum	15
International Prostate Forum	17
Innovations in Men's Health	22
Urologic Oncology Research Symposia	23



Disclosure of Relevant Financial Relationships *Urologic Care for the Advanced Practice Provider*

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months.

An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships listed below have been mitigated.

Name	Company Name	Relationship Type	End Date
Arruda, John Brandon	No relevant financial relationships to disclose		
Brewer, Taylor	No relevant financial relationships to disclose		
Chung, Doreen Eleanor	No relevant financial relationships to disclose		
Chuong, Lisa	No relevant financial relationships to disclose		
Dziuba, Katherine Anna	No relevant financial relationships to disclose		
Geyer, Holly	No relevant financial relationships to disclose		
Hellwig, Michelle	No relevant financial relationships to disclose		
Higareda, Sophia	No relevant financial relationships to disclose		
Hughes, Corinna	No relevant financial relationships to disclose		
Kovarik III, James R.	No relevant financial relationships to disclose		
Lewis, Jennifer	No relevant financial relationships to disclose		
Lowe, Karen	No relevant financial relationships to disclose		
Luckenbaugh, Amy N.	No relevant financial relationships to disclose		
Madore, Les	No relevant financial relationships to disclose		
Moore, JoAnn M.	No relevant financial relationships to disclose		
Quallich, Susanne	Coloplast	Consultant or Advisor	Current
	Endo Pharmaceuticals	Consultant or Advisor	Current
Ruzimovsky, Marina	No relevant financial relationships to disclose		
Sandhu, Jaspreet Singh	No relevant financial relationships to disclose		
Shafei, Marissa Leigh	No relevant financial relationships to disclose		
Shapiro, Rachel	No relevant financial relationships to disclose		
Smith, Kristin	No relevant financial relationships to disclose		
Sterling, Brandon	No relevant financial relationships to disclose		
Wayne, Kevin A.	No relevant financial relationships to disclose		
Williams, Tamika	No relevant financial relationships to disclose		
Zubert, Tricia	No relevant financial relationships to disclose		



Disclosure of Relevant Financial Relationships *Basic Science Symposium*

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months.

An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The AUA must determine if the individual's relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships listed below have been mitigated.

Name	Company Name	Relationship Type	End Date
Al-Ahmadie, Hikmat	AstraZeneca	Consultant or Advisor	Current
	Paige.AI	Consultant or Advisor	Current
Chen, Haiqi	No relevant financial relationships to disclose		
Herr II, Bruce W.	No relevant financial relationships to disclose		
Jain, Sanjay	No relevant financial relationships to disclose		
Kaplan, Steven Abraham	No relevant financial relationships to disclose		
Mitchell, Thomas	No relevant financial relationships to disclose		
Solit, David B.	No relevant financial relationships to disclose		
Strand, Douglas	No relevant financial relationships to disclose		
Ting, Angela	No relevant financial relationships to disclose		
Yates III, Clayton	Regeneron	Meeting Participant or Lecturer	02/28/2023
	QED Therapeutics	Consultant or Advisor	10/01/2023
	PreludeDX	Consultant or Advisor	Current



Disclosure of Relevant Financial Relationships *Bladder Cancer Forum*

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months.

An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The AUA must determine if the individual's relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships listed below have been mitigated.

Name	Company Name	Relationship Type	End Date
Baack Kukreja, Janet	No relevant financial relationships to disclose		
Bree, Kelly	No relevant financial relationships to disclose		
Cookson, Michael S.	No relevant financial relationships to disclose		
Daneshmand, Siamak	Johnson and Johnson	Scientific Study or Trial	04/01/2023
	Karl Storz	Consultant or Advisor	11/04/2023
	BMS	Consultant or Advisor	Current
	CG Oncology	Consultant or Advisor	Current
	Ferring	Consultant or Advisor	Current
	Janssen	Consultant or Advisor	Current
	Pacific Edge	Consultant or Advisor	Current
	Pfizer	Meeting Participant or Lecturer	Current
	Photocure	Consultant or Advisor	Current
	Protara	Consultant or Advisor	Current
	Sesen	Consultant or Advisor	Current
	Urogen	Consultant or Advisor	Current
Gontero, Paolo	Ferring	Consultant or Advisor	Current
	IPSEN	Meeting Participant or Lecturer	Current
	Janssen	Scientific Study or Trial	Current
	MEDAC	Consultant or Advisor	Current
	Nucleix	Consultant or Advisor	Current
	Photocure	Consultant or Advisor	Current
Grivas, Petros	BostonGene	Consultant or Advisor	06/04/2022
	PureTech	Consultant or Advisor	06/15/2022
	G1 Therapeutics	Consultant or Advisor	08/17/2022
	Aadi Bioscience	Consultant or Advisor	08/26/2022
	CG Oncology	Consultant or Advisor	12/01/2022
	Mirati Therapeutics	Scientific Study or Trial	01/23/2023
	ImmunityBio	Consultant or Advisor	02/07/2023
	Asieris Pharmaceuticals	Consultant or Advisor	02/15/2023
	Pfizer	Consultant or Advisor	03/23/2023



Disclosure of Relevant Financial Relationships *Bladder Cancer Forum*

Name	Company Name	Relationship Type	End Date
Grivas, Petros (cont.)	QED Therapeutics	Scientific Study or Trial	05/04/2023
	Janssen	Consultant or Advisor	05/16/2023
	Fresenius Kabi	Consultant or Advisor	06/01/2023
	SeaGen	Consultant or Advisor	10/23/2023
	Abbvie	Consultant or Advisor	01/24/2024
	Gilead	Consultant or Advisor	01/24/2024
	AstraZeneca	Consultant or Advisor	01/25/2024
	Bristol-Myers Squibb	Consultant or Advisor	01/26/2024
	Roche	Consultant or Advisor	01/27/2024
	Merck & Co	Consultant or Advisor	02/28/2024
	Acrivon Therapeutics	Scientific Study or Trial	Current
	ALX Oncology	Scientific Study or Trial	Current
	Astellas Pharma	Consultant or Advisor	Current
	EMD Serono	Consultant or Advisor	Current
	Genentech	Scientific Study or Trial	Current
	Strata Oncology	Consultant or Advisor	Current
Gupta, Shilpa	No relevant financial relationships to disclose		
Kamat, Ashish M.	No relevant financial relationships to disclose		
Konety, Badrinath R.	No relevant financial relationships to disclose		
Lerner, Seth Paul	QED Therapeutics	Scientific Study or Trial	12/18/2022
	Protara	Consultant or Advisor	09/14/2023
	Incyte	Consultant or Advisor	10/29/2023
	Astra Zeneca	Consultant or Advisor	11/05/2024
	Aura Biosciences	Scientific Study or Trial	Current
	BMS	Consultant or Advisor	Current
	C2i Genomics	Consultant or Advisor	Current
	Ferring	Consultant or Advisor	Current
	FKD	Scientific Study or Trial	Current
	Pfizer	Consultant or Advisor	Current
	Roche/Genentech	Scientific Study or Trial	Current
	Stimit	Consultant or Advisor	Current
	UpToDate	Health Publishing	Current
	Vaxiion	Consultant or Advisor	Current
	Vaxiion	Scientific Study or Trial	Current
	Verity	Consultant or Advisor	Current
	Li, Roger	Eli Lilly	Investment Interest
Arquer Diagnostics		Consultant or Advisor	01/20/2023
Urogen Pharma		Consultant or Advisor	01/22/2023



Disclosure of Relevant Financial Relationships *Bladder Cancer Forum*

Name	Company Name	Relationship Type	End Date
Li, Roger (cont.)	Beam Therapeutics	Investment Interest	Current
	BMS	Scientific Study or Trial	Current
	Crispr Therapeutics	Investment Interest	Current
	Decipher	Scientific Study or Trial	Current
	Guardant Health	Investment Interest	Current
	Intellia Therapeutics	Investment Interest	Current
	Predicine	Scientific Study or Trial	Current
Lotan, Yair	Abbvie	Consultant or Advisor	Current
	Ambu	Consultant or Advisor	Current
	Astra Zeneca	Consultant or Advisor	Current
	Aura Biosciences	Consultant or Advisor	Current
	C2I genomics	Consultant or Advisor	Current
	CAPs Medical	Consultant or Advisor	Current
	CG Oncology	Consultant or Advisor	Current
	Convergent Genomics	Consultant or Advisor	Current
	Engene	Consultant or Advisor	Current
	Fergene	Consultant or Advisor	Current
	Merck Inc	Consultant or Advisor	Current
	Nonagen	Consultant or Advisor	Current
	Nucleix	Consultant or Advisor	Current
	On Target Lab	Consultant or Advisor	Current
	Pacific Edge	Consultant or Advisor	Current
	Pfizer	Consultant or Advisor	Current
	Photocure	Consultant or Advisor	Current
	Promis Diagnostics	Consultant or Advisor	Current
	Seattle Genetics	Consultant or Advisor	Current
	Stimit	Consultant or Advisor	Current
	Uroessentials	Consultant or Advisor	Current
	Urogen	Consultant or Advisor	Current
	Uroviu	Consultant or Advisor	Current
Valar Lab	Consultant or Advisor	Current	
Verity Pharmaceuticals	Consultant or Advisor	Current	
Vessi Medical	Consultant or Advisor	Current	
Virtuoso Surgical	Consultant or Advisor	Current	
Mariappan, Paramanathan	Medac Pharma	Consultant or Advisor	Current
Necchi, Andrea	Merck	Consultant or Advisor	Current
Oualla, Karima	No relevant financial relationships to disclose		



Disclosure of Relevant Financial Relationships *Bladder Cancer Forum*

Name	Company Name	Relationship Type	End Date
Palou, Juan	No relevant financial relationships to disclose		
Pohar, Kamal S.	Merck	Consultant or Advisor	03/14/2025
	CG Oncology	Consultant or Advisor	Current
	Photocure	Consultant or Advisor	Current
Porten, Sima Prabodh	Coloplast	Consultant or Advisor	10/31/2022
	AstraZeneca	Consultant or Advisor	Current
	Pacific Edge	Consultant or Advisor	Current
	Photocure	Scientific Study or Trial	Current
	Stryker	Consultant or Advisor	Current
Psutka, Sarah P.	Medtronic	Meeting Participant or Lecturer	06/29/2022
	ImmunityBio	Consultant or Advisor	02/27/2023
	Merck	Consultant or Advisor	03/19/2024
	CG Oncology	Consultant or Advisor	Current
	Janssen	Scientific Study or Trial	Current
Shore, Neal D.	Phosphorus	Consultant or Advisor	08/01/2022
	Akido	Consultant or Advisor	01/01/2023
	Clovis Oncology	Consultant or Advisor	01/01/2023
	Exact Sciences	Consultant or Advisor	01/01/2023
	GConcology	Consultant or Advisor	01/01/2023
	NGM Bio	Consultant or Advisor	01/01/2023
	Sesen Bio	Consultant or Advisor	01/01/2023
	Vaxiion	Consultant or Advisor	01/01/2023
	Vessi	Consultant or Advisor	01/01/2023
	Myovant	Consultant or Advisor	02/01/2024
	Pacific Edge	Consultant or Advisor	02/01/2024
	CG Oncology	Consultant or Advisor	03/12/2024
	Clovis	Consultant or Advisor	03/12/2024
	Foundation Medicine	Consultant or Advisor	03/12/2024
	Genentech	Scientific Study or Trial	02/01/2024
		Consultant or Advisor	03/12/2024
	Guardant	Consultant or Advisor	03/12/2024
	ImmunityBio	Consultant or Advisor	03/12/2024
	Incyte	Consultant or Advisor	03/12/2024
	Nonagen	Consultant or Advisor	03/12/2024
Nymox	Consultant or Advisor	03/12/2024	
Pacific Edge	Consultant or Advisor	03/12/2024	
Profound	Consultant or Advisor	03/12/2024	
Abbvie	Consultant or Advisor	Current	



Disclosure of Relevant Financial Relationships *Bladder Cancer Forum*

Name	Company Name	Relationship Type	End Date
Shore, Neal D. (cont.)	Accord	Consultant or Advisor	Current
	Amgen	Consultant or Advisor	Current
	Antev	Consultant or Advisor	Current
	Arquer	Consultant or Advisor	Current
	Asieris	Consultant or Advisor	Current
	Astellas	Consultant or Advisor	Current
	AstraZeneca	Consultant or Advisor	Current
	Aura Biosciences	Consultant or Advisor	Current
	Bayer	Consultant or Advisor	Current
	BioProtect	Consultant or Advisor	Current
	Boston Scientific	Consultant or Advisor	Current
	Bristol Myers Squibb	Consultant or Advisor	Current
	Clarity Diagnostics	Consultant or Advisor	Current
	Cold Genesys	Consultant or Advisor	Current
	Dendreon	Consultant or Advisor	Current
	EMD Serono	Consultant or Advisor	Current
	Exact Imaging	Consultant or Advisor	Current
	FerGene	Consultant or Advisor	Current
	Ferring	Consultant or Advisor	Current
	FIZE Medical	Consultant or Advisor	Current
	Guardant	Consultant or Advisor	Current
	Invitae	Consultant or Advisor	Current
	Janssen	Consultant or Advisor	Current
	Lantheus	Consultant or Advisor	Current
	Lilly	Consultant or Advisor	Current
	MDxHealth	Consultant or Advisor	Current
	Merck	Consultant or Advisor	Current
	Minomic	Consultant or Advisor	Current
	Myriad	Consultant or Advisor	Current
	Novartis	Consultant or Advisor	Current
	Palette Life Sciences	Consultant or Advisor	Current
	Pfizer	Consultant or Advisor	Current
	Photocure	Consultant or Advisor	Current
Investment Interest		Current	
PlatformQ	Consultant or Advisor	Current	
Promaxo	Consultant or Advisor	Current	
Propella	Consultant or Advisor	Current	
Protara	Consultant or Advisor	Current	



Disclosure of Relevant Financial Relationships *Bladder Cancer Forum*

Name	Company Name	Relationship Type	End Date
Shore, Neal D. (cont.)	Sanofi Genzyme	Consultant or Advisor	Current
	Siemens	Consultant or Advisor	Current
	Speciality Networks	Consultant or Advisor	Current
	Sumitomo	Consultant or Advisor	Current
	Telix	Consultant or Advisor	Current
	Tolmar	Consultant or Advisor	Current
	Urogen	Consultant or Advisor	Current
Stenzl, Arnulf	Alere	Consultant or Advisor	Current
	Amgen	Scientific Study or Trial	Current
	Astellas	Scientific Study or Trial	Current
		Consultant or Advisor	Current
	AstraZeneca	Scientific Study or Trial	Current
	Bayer Ag	Scientific Study or Trial	Current
	Bristol-Myers Squibb	Consultant or Advisor	Current
	Cepheid	Scientific Study or Trial	Current
	CureVac	Scientific Study or Trial	Current
	Ferring	Consultant or Advisor	Current
		Meeting Participant or Lecturer	Current
	GenomeDx Biosciences	Scientific Study or Trial	Current
	Ipsen	Consultant or Advisor	Current
	Johnson & Johnson	Scientific Study or Trial	Current
	Karl Storz GmbH	Consultant or Advisor	Current
Novartis	Scientific Study or Trial	Current	
Svatek, Robert Scott	CG Oncology	Consultant or Advisor	Current
	Ferring Pharmaceuticals	Consultant or Advisor	Current
	Verity Pharmaceuticals	Consultant or Advisor	Current
Taylor III, John Arthur	No relevant financial relationships to disclose		
Teoh, Jeremy	AstraZeneca	Scientific Study or Trial	Current
	Janssen	Scientific Study or Trial	Current
	Olympus	Scientific Study or Trial	Current
	Phase Scientific	Consultant or Advisor	Current
	Procept Biorobotics	Consultant or Advisor	Current
Williams, Stephen B.	Johnson & Johnson/Janssen	Other-Travel and lodging	Current
	Merck	Consultant or Advisor	Current
	Photocure	Consultant or Advisor	Current
	Valar Labs	Consultant or Advisor	Current
Zlotta, Alexandre R.	Ferring	Consultant or Advisor	Current
	Janssen	Meeting Participant or Lecturer	Current



Disclosure of Relevant Financial Relationships *Bladder Cancer Forum*

Name	Company Name	Relationship Type	End Date
Zlotta, Alexandre (cont.)	miR Scientific	Consultant or Advisor	Current
	Myovant Sciences	Meeting Participant or Lecturer	Current
	Photocure	Consultant or Advisor	Current
	Theralase	Consultant or Advisor	Current
	Tolmar	Consultant or Advisor	Current
	Tyra Biosciences	Consultant or Advisor	Current
	Verity Pharmaceuticals	Consultant or Advisor	Current



Disclosure of Relevant Financial Relationships *Challenges for Urologic Research*

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months.

An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The AUA must determine if the individual's relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships listed below have been mitigated.

Name	Company Name	Relationship Type	End Date
Arthur, Michelle Mravec	No relevant financial relationships to disclose		
Copp, Hillary L.	No relevant financial relationships to disclose		
Harris, Kelly T.	No relevant financial relationships to disclose		
Johnston, Ashley W.	No relevant financial relationships to disclose		
Queally, Jennifer	No relevant financial relationships to disclose		
Roth, Joshua	No relevant financial relationships to disclose		
Stoffel, John T.	The Flume Catheter Company	Consultant or Advisor	Current
	SpineX	Consultant or Advisor	Current
	Coloplast	Scientific Study or Trial	Current
Streur, Courtney Shepard	No relevant financial relationships to disclose		
Struwe, Sara	No relevant financial relationships to disclose		
Szymanski, Konrad M.	No relevant financial relationships to disclose		
Van Speybroeck, Alexander	No relevant financial relationships to disclose		
Weaver, John	No relevant financial relationships to disclose		
Wood, Dan N.	No relevant financial relationships to disclose		
Wood, Hadley Merrideth	No relevant financial relationships to disclose		



Disclosure of Relevant Financial Relationships *Diversity, Equity and Inclusion Forum*

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months.

An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The AUA must determine if the individual's relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships listed below have been mitigated.

Name	Relationship
Bologna, Eugenio	No relevant financial relationships to disclose
Bresler, Larissa	No relevant financial relationships to disclose
Chehroudi, Cyrus	No relevant financial relationships to disclose
Eldin, Maya	No relevant financial relationships to disclose
Griebing, Tomas Lindor	No relevant financial relationships to disclose
Grunewald, Nathan	No relevant financial relationships to disclose
McNeil, Brian Keith	No relevant financial relationships to disclose
Milhouse, Olufenwa Juanita	No relevant financial relationships to disclose
Murphy, Adam Bryant	No relevant financial relationships to disclose
Rodriguez, Larissa V.	No relevant financial relationships to disclose
Salami, Simpa Samuel	No relevant financial relationships to disclose
Santiago-Lastra, Yahir A.	No relevant financial relationships to disclose
Smith-Mathus, Gjanje L.	No relevant financial relationships to disclose
Vieira, Jaime	No relevant financial relationships to disclose
Zappia, Jason	No relevant financial relationships to disclose



Disclosure of Relevant Financial Relationships

The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines & Case-Based Discussion

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The AUA must determine if the individual's relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships listed below have been mitigated.

Name	Company Name	Relationship Type	End Date
Boorjian, Stephen A.	FerGene	Consultant or Advisor	08/01/2023
	ArTara	Consultant or Advisor	Current
	Prokarium	Consultant or Advisor	Current
	Ferring	Consultant or Advisor	Current
Cookson, Michael	Lantheus	Consultant or Advisor	09/24/2022
	Prokarium	Consultant or Advisor	10/26/2022
	Janssen	Consultant or Advisor	11/30/2022
	Nonagen	Consultant or Advisor	07/11/2023
	Pfizer	Consultant or Advisor	Current
	Progenics	Consultant or Advisor	Current
Gomella, Leonard G.	Exelixis	Consultant or Advisor	08/01/2022
	AstraZeneca	Consultant or Advisor	Current
	Blue Earth	Consultant or Advisor	Current
	Lantheus	Consultant or Advisor	Current
	MDx Health	Consultant or Advisor	Current
	Merck	Health Publishing	Current
		Consultant or Advisor	Current
Heath, Elisabeth	Astellas	Consultant or Advisor	Current
	Astra Zeneca	Consultant or Advisor	Current
	Janssen	Consultant or Advisor	Current
	Sanofi	Consultant or Advisor	Current
	Seattle Genetics	Consultant or Advisor	Current
Jarrad, David F.	No relevant financial relationships to disclose		
Lang, Joshua	Cullgen	Consultant or Advisor	10/21/2022
	4D Pharma	Consultant or Advisor	12/16/2022
	Sanofi	Consultant or Advisor	02/16/2023
	Jansen	Consultant or Advisor	09/06/2023
	AstraZeneca	Consultant or Advisor	Current
	Foundation Medicine	Consultant or Advisor	Current
	Pfizer	Consultant or Advisor	Current
Moses, Kelvin A.	No relevant financial relationships to disclose		



Disclosure of Relevant Financial Relationships

The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines & Case-Based Discussion

Name	Company Name	Relationship Type	End Date
Scarpato, Kristen R.	No relevant financial relationships to disclose		
Stratton, Kelly L.	Merck	Meeting Participant or Lecturer	02/03/2023
		Consultant or Advisor	Current
	Ebix	Consultant or Advisor	02/21/2023
	Bayer	Meeting Participant or Lecturer	09/30/2023
	Janssen	Consultant or Advisor	11/30/2023



Disclosure of Relevant Financial Relationships *History of Urology Forum*

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months.

An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The AUA must determine if the individual's relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships listed below have been mitigated.

Name	Relationship
Alam, Ahmad	No relevant financial relationships to disclose
Alshak, Mark	No relevant financial relationships to disclose
Appleton, Ashley	No relevant financial relationships to disclose
Ayer, Myles	No relevant financial relationships to disclose
Badawi, Jasmin Katrin	No relevant financial relationships to disclose
Burnett, Arthur	No relevant financial relationships to disclose
Caldamone, Anthony	No relevant financial relationships to disclose
Chen, Katherina	No relevant financial relationships to disclose
Creighton, Christian	No relevant financial relationships to disclose
Desouky, Elsayad	No relevant financial relationships to disclose
DeWitt-Foy, Molly	No relevant financial relationships to disclose
Dielubanza, Elodi	No relevant financial relationships to disclose
Eckenrode, John	No relevant financial relationships to disclose
Grutman, Aurora	No relevant financial relationships to disclose
Hall, Bryan	No relevant financial relationships to disclose
Hines, Laena	No relevant financial relationships to disclose
Hunt, Trevor	No relevant financial relationships to disclose
Kulkarni, Ashwin	No relevant financial relationships to disclose
Lavold, Abigail	No relevant financial relationships to disclose
Lokeshwar, Soum	No relevant financial relationships to disclose
Majdalany, Sami	No relevant financial relationships to disclose
Martinez, Mariela	No relevant financial relationships to disclose
Moll, Friedrich	No relevant financial relationships to disclose
Moran, Mike	No relevant financial relationships to disclose
Olive, Elizabeth	No relevant financial relationships to disclose
Osinski, Thomas	No relevant financial relationships to disclose
Pardini-Furtado, Thiago	No relevant financial relationships to disclose
Patel, Sutchin	No relevant financial relationships to disclose
Philips, John	No relevant financial relationships to disclose
Pranikoff, Kevin	No relevant financial relationships to disclose
Rabinowitz, Ron	No relevant financial relationships to disclose



Disclosure of Relevant Financial Relationships *History of Urology Forum*

Name	Company Name	Relationship Type	End Date
Razdan, Shirin	No relevant financial relationships to disclose		
Reddy, Raghuram	No relevant financial relationships to disclose		
Roach, Mack	No relevant financial relationships to disclose		
Rubano, Amanda	No relevant financial relationships to disclose		
Smith, Loren	No relevant financial relationships to disclose		
Smith, Shelby	No relevant financial relationships to disclose		
Stump, Jeffrey	No relevant financial relationships to disclose		
Swayze, Aden	No relevant financial relationships to disclose		
Udedibia, Emeka	No relevant financial relationships to disclose		
Ulchakar, James	Fortec Medical	Consultant or Advisor	Current
Wang, Susanna	No relevant financial relationships to disclose		
Xu, Jonathan	No relevant financial relationships to disclose		



Disclosure of Relevant Financial Relationships *International Prostate Forum*

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months.

An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The AUA must determine if the individual's relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships listed below have been mitigated.

Name	Company Name	Relationship Type	End Date
Agarwal, Neeraj	No relevant financial relationships to disclose		
Calais, Jeremie	Amgen	Consultant or Advisor	12/31/2022
	Blue Earth Diagnostics	Consultant or Advisor	12/31/2022
	Curium Pharma	Consultant or Advisor	12/31/2022
	Monrol	Meeting Participant or Lecturer	12/31/2022
	Sanofi	Consultant or Advisor	12/31/2022
	Sofie	Consultant or Advisor	12/31/2022
	Astellas	Consultant or Advisor	12/31/2023
	Byer	Consultant or Advisor	12/31/2023
	GE Healthcare	Consultant or Advisor	12/31/2023
	Janssen Pharmaceuticals	Consultant or Advisor	12/31/2023
	Lantheus	Consultant or Advisor	12/31/2023
		Scientific Study or Trial	12/31/2023
	Novartis	Scientific Study or Trial	12/31/2023
		Consultant or Advisor	12/31/2023
	Pfizer	Consultant or Advisor	12/31/2023
	POINT biopharma	Consultant or Advisor	12/31/2023
		Scientific Study or Trial	12/31/2023
	Radiomedix	Consultant or Advisor	12/31/2023
Telix Pharmaceuticals	Consultant or Advisor	12/31/2023	
Varian	Consultant or Advisor	12/31/2023	
Chiu, Peter Ka Fung	No relevant financial relationships to disclose		
Choi, Seungtaek	No relevant financial relationships to disclose		
Davis, John Warren	Janssen	Scientific Study or Trial	Current
	GenomeDx	Scientific Study or Trial	Current
Eberli, Daniel	Bayer	Consultant or Advisor	06/20/2022
	Myriad	Consultant or Advisor	07/06/2022
	Janssen Cilag AG	Consultant or Advisor	10/27/2022
	IACULIS	Consultant or Advisor	03/28/2023
	Astellas Pharma AG	Consultant or Advisor	12/12/2023



Disclosure of Relevant Financial Relationships *International Prostate Forum*

Name	Company Name	Relationship Type	End Date
Efstathiou, Eleni	Oric Pharma	Consultant or Advisor	12/01/2022
	Tolmar	Consultant or Advisor	12/01/2022
	Innocrin Pharma	Consultant or Advisor	01/01/2023
	Astellas	Consultant or Advisor	Current
	AstraZeneca	Consultant or Advisor	Current
	Bayer	Consultant or Advisor	Current
	Janssen-Cilag	Consultant or Advisor	Current
	MSD	Consultant or Advisor	Current
	Sanofi	Consultant or Advisor	Current
	Takeda	Consultant or Advisor	Current
Freedland, Stephen J.	A3P	Consultant or Advisor	Current
	Astellas	Consultant or Advisor	Current
	AstraZeneca	Consultant or Advisor	Current
	Bayer	Consultant or Advisor	Current
	Exact Sciences	Consultant or Advisor	Current
	Exosome	Consultant or Advisor	Current
	Hessian Labs	Consultant or Advisor	Current
	Janssen	Consultant or Advisor	Current
	Lilly	Consultant or Advisor	Current
	Lynx	Consultant or Advisor	Current
	Merck	Consultant or Advisor	Current
	Myovant	Consultant or Advisor	Current
	Pfizer	Consultant or Advisor	Current
	Sanofi	Consultant or Advisor	Current
Tempus	Consultant or Advisor	Current	
Garraway, Isla	No relevant financial relationships to disclose		
Gleave, Martin Edwin	Sikta Pharmaceuticals	Other-Founder	09/01/2023
	Abbvie	Consultant or Advisor	Current
	Astellas	Consultant or Advisor	Current
	Bayer	Consultant or Advisor	Current
	GDx	Consultant or Advisor	Current
	Janssen	Consultant or Advisor	Current
	Roche	Consultant or Advisor	Current
	Sanofi-Aventis	Consultant or Advisor	Current
	Tersera	Consultant or Advisor	Current
Gonzalez, Ricardo R.	Boston Scientific	Consultant or Advisor	Current
	Coloplast	Consultant or Advisor	Current
	Procept Biorobotics	Investment Interest	Current



Disclosure of Relevant Financial Relationships *International Prostate Forum*

Name	Company Name	Relationship Type	End Date
Gonzalez, Ricardo (cont.)	Prodeon Medical	Scientific Study or Trial	Current
	ProVerum Limited	Scientific Study or Trial	Current
	Zenflow	Scientific Study or Trial	Current
Graefen, Markus	No relevant financial relationships to disclose		
Greene, Kirsten Lynn	miR scientific	Consultant or Advisor	07/01/2022
	Johnson & Johnson	Consultant or Advisor	Current
	Intuitive	Consultant or Advisor	Current
Hamdy, Freddie Charles	Ipsen Pharma SAS	Meeting Participant or Lecturer	09/15/2023
	Pfizer	Meeting Participant or Lecturer	01/19/2024
	Intuitive Surgical	Consultant or Advisor	Current
Hong, Sung Kyu	No relevant financial relationships to disclose		
Iagaru, Andrei	Advanced Accelerator Applications	Scientific Study or Trial	Current
	Endocyte	Scientific Study or Trial	Current
	Clarity Pharmaceuticals	Consultant or Advisor	Current
	Alpha9 Tx	Consultant or Advisor	Current
	Radionetics	Consultant or Advisor	Current
Jia, Angela	No relevant financial relationships to disclose		
Loeb, Stacy	No relevant financial relationships to disclose		
Logothetis, Christopher J.	Astellas	Consultant or Advisor	01/01/2024
	Bristol-Myers Squibb	Consultant or Advisor	01/01/2024
	Johnson & Johnson	Consultant or Advisor	01/01/2024
	Pfizer	Consultant or Advisor	01/01/2024
	Amgen	Consultant or Advisor	Current
	Bayer	Consultant or Advisor	Current
	Boehringer Ingelheim	Consultant or Advisor	Current
	Novartis	Consultant or Advisor	Current
		Scientific Study or Trial	Current
	Exelixis	Consultant or Advisor	Current
	Merck	Consultant or Advisor	Current
	Sharp & Dohme	Consultant or Advisor	Current
	Aragon	Scientific Study or Trial	Current
	Janssen	Scientific Study or Trial	Current
Oric Pharma	Scientific Study or Trial	Current	
Mendoza-Valdes, Arturo	Weswer Pharma	Meeting Participant or Lecturer	11/30/2022
	Sanfer	Meeting Participant or Lecturer	12/30/2022
	AstraZeneca	Meeting Participant or Lecturer	Current
	Bayer	Consultant or Advisor	Current
	GSK	Meeting Participant or Lecturer	Current



Disclosure of Relevant Financial Relationships *International Prostate Forum*

Name	Company Name	Relationship Type	End Date
Mendoza-Valde (cont.)	Janssen	Meeting Participant or Lecturer	Current
Montorsi, Francesco	No relevant financial relationships to disclose		
Moul, Judd W.	Astellas	Meeting Participant or Lecturer	Current
	Bayer	Consultant or Advisor	Current
	Blue Earth Diagnostics	Meeting Participant or Lecturer	Current
	Dendreon	Meeting Participant or Lecturer	Current
	Exosome Dx	Meeting Participant or Lecturer	Current
	Janssen	Meeting Participant or Lecturer	Current
	Myovant	Scientific Study or Trial	Current
	Pfizer	Scientific Study or Trial	Current
	Sanofi-Aventis	Meeting Participant or Lecturer	Current
	Theralogix	Consultant or Advisor	Current
	Tolmar	Consultant or Advisor	Current
Pilie Patrick G	Janssen	Consultant or Advisor	11/08/2023
Radtke, Jan Philipp	Janssen Pharmaceuticals	Consultant or Advisor	12/31/2024
	Amgen	Consultant or Advisor	Current
	Apogepha	Consultant or Advisor	Current
	Astellas Pharma	Consultant or Advisor	Current
	Bayer Healthineers	Consultant or Advisor	Current
	Bender Gruppe	Meeting Participant or Lecturer	Current
	Dr. Wolf, Beckelmann und Partner mbH	Meeting Participant or Lecturer	Current
	Novartis	Consultant or Advisor	Current
	Saegeling Medizintechnik GmbH	Consultant or Advisor	Current
	Siemens Healthineers	Meeting Participant or Lecturer	Current
Reiter, Robert Evan	Genomic Health	Consultant or Advisor	07/01/2022
	Janssen	Consultant or Advisor	11/28/2022
	Bayer	Consultant or Advisor	Current
	ImaginAb Corporation	Stock Option	Current
	Lantheus	Consultant or Advisor	Current
	Pfizer	Consultant or Advisor	Current
	Point Biopharma	Consultant or Advisor	Current
Sanchez-Salas, Rafael	Angiodynamics	Consultant or Advisor	Current
	EDAP TMS	Meeting Participant or Lecturer	Current
	ExactImaging	Consultant or Advisor	Current
Sieber, Paul R.	Hinova	Scientific Study or Trial	07/01/2022
	Exact Sciences	Scientific Study or Trial	08/31/2022



Disclosure of Relevant Financial Relationships *International Prostate Forum*

Name	Company Name	Relationship Type	End Date
Sieber, Paul (cont.)	AstraZeneca	Scientific Study or Trial	Current
	Bayer	Scientific Study or Trial	Current
	CG Therapeutics	Scientific Study or Trial	Current
	Dendreon	Scientific Study or Trial	Current
	Ferring	Scientific Study or Trial	Current
	Janssen	Scientific Study or Trial	Current
	Medivation/Astellas	Scientific Study or Trial	Current
	Merck	Scientific Study or Trial	Current
	Myovant	Scientific Study or Trial	Current
	Oric	Scientific Study or Trial	Current
	Pfizer/Medivation	Scientific Study or Trial	Current
Tang, Chad	Siemens Healthineers	Consultant or Advisor	01/11/2023
	Lantheus	Consultant or Advisor	05/12/2023
	Boston Scientific	Consultant or Advisor	09/25/2023
	Molli Surgical	Consultant or Advisor	10/03/2023
	Telix	Consultant or Advisor	10/04/2023
Tilki, Derya	Pfizer	Meeting Participant or Lecturer	05/07/2022
	miR Scientific	Consultant or Advisor	07/31/2022
	Apogepha	Meeting Participant or Lecturer	07/31/2023
	A3P Biomedical	Consultant or Advisor	Current
	AstraZeneca	Consultant or Advisor	Current
Weiner, Adam	No relevant financial relationships to disclose		



Disclosure of Relevant Financial Relationships *Innovations in Men's Health*

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months.

An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The AUA must determine if the individual's relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships listed below have been mitigated.

Name	Company Name	Relationship Type	End Date
Eisenberg, Michael Louis	Legacy	Consultant or Advisor	02/13/2026
Hotaling, James M.	Carrot Fertility	Consultant or Advisor	Current
	Maximus	Consultant or Advisor	Current
	Turtle Health	Consultant or Advisor	Current
Kohler, Tobias Steen	American Medical Systems	Consultant or Advisor	05/06/2024
	Coloplast	Consultant or Advisor	05/06/2024
	Boston Scientific	Consultant or Advisor	05/06/2024
Kudithipudi, Dhiresha	No relevant financial relationships to disclose		
Lipshultz, Larry I.	No relevant financial relationships to disclose		
Lue, Tom F.	No relevant financial relationships to disclose		
Niederberger, Craig Stuart	Contraline	Consultant or Advisor	Current
	Ferring Pharmaceuticals	Scientific Study or Trial	Current
	ReproNovo	Consultant or Advisor	Current
Trost, Landon	No relevant financial relationships to disclose		



Disclosure of Relevant Financial Relationships *Urologic Oncology Research Symposia*

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The AUA must determine if the individual's relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships listed below have been mitigated.

Name	Company Name	Relationship Type	End Date
Cary, Clint	No relevant financial relationships to disclose		
Cragun, Deborah	No relevant financial relationships to disclose		
Dunsmore, Jennifer	No relevant financial relationships to disclose		
Ellis, Shellie	Pfizer	Consultant or Advisor	Current
Gaylis, Franklin David	No relevant financial relationships to disclose		
Ghani, Khurshid R.	No relevant financial relationships to disclose		
Hysong, Sylvia Janette	No relevant financial relationships to disclose		
Loeb, Stacy	No relevant financial relationships to disclose		
Maclennan, Steven	No relevant financial relationships to disclose		
Makarov, Danil Victor	No relevant financial relationships to disclose		
Nielsen, Matthew Edward	No relevant financial relationships to disclose		
Psutka, Sarah P.	No relevant financial relationships to disclose		
Sales, Anne	No relevant financial relationships to disclose		
Shelton, Jeremy Bradford	No relevant financial relationships to disclose		
Skolarus, Ted A.	No relevant financial relationships to disclose		
Smaldone, Marc Christopher	No relevant financial relationships to disclose		
Stensland, Kristian D.	No relevant financial relationships to disclose		